Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond
Kyriakos Dimitriadis, Eleni Adamopoulou, Nikolaos Pyrpyris, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 9, Iss. 8, pp. 741-757
Closed Access | Times Cited: 18

Showing 18 citing articles:

SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 35
Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies
N Mylonas, Panagiota Nikolaou, Paschalis Karakasis, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7274-7274
Open Access | Times Cited: 17
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Giovanna Gallo, Massimo Volpe
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2484-2484
Open Access | Times Cited: 10
Effects of Sympathetic Denervation in Metabolism Regulation: A Novel Approach for the Treatment of MASLD?
Kyriakos Dimitriadis, Panagιotis Iliakis, Angeliki Vakka, et al.
Cardiology in Review (2025)
Closed Access | Times Cited: 1
ANOCA updated: From pathophysiology to modern clinical practice
Kyriakos Dimitriadis, Nikolaos Pyrpyris, Athanasios Sakalidis, et al.
Cardiovascular revascularization medicine (2024)
Closed Access | Times Cited: 4
Endothelial Markers in Type 2 Diabetic Patients with Acute Decompensated Heart Failure: A Pilot Study
Martin Jozef Péč, Jakub Jurica, Tomáš Bolek, et al.
Metabolites (2025) Vol. 15, Iss. 2, pp. 91-91
Open Access
Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class
Steven Hopkins, Faiz Baqai, Saivaroon Gajagowni, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2025) Vol. 30
Open Access
The SGLT2 inhibitor canagliflozin attenuates mitochondrial oxidative stress and alterations of calcium handling induced by high glucose in human cardiac fibroblasts
Fahimeh Varzideh, Urna Kansakar, Scott Wilson, et al.
Cell Cycle (2025), pp. 1-8
Closed Access
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
Maria Antonietta Riemma, Elena Mele, Maria Donniacuo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
David Fitchett, Bernard Zinman, Silvio E. Inzucchi, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension
Matúš Sýkora, Barbara Szeiffová Bačová, Katarína Andelová, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3275-3275
Open Access | Times Cited: 2
The role of coronary microcirculation in heart failure with preserved ejection fraction: An unceasing odyssey
Kyriakos Dimitriadis, Panagiotis Theofilis, Georgios Koutsopoulos, et al.
Heart Failure Reviews (2024)
Closed Access | Times Cited: 2
Preclinical systolic dysfunction relating to ankle-brachial index among high-risk PAD population with preserved left ventricular ejection fraction
Yueh‐Hung Lin, Kuo‐Tzu Sung, Cheng‐Ting Tsai, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Could the administration of SGLT2i agents serve as a viable prophylactic approach against CNI-induced toxicities?
Emad Molaei, Ali Molaei, Simin Dashti‐Khavidaki, et al.
Medical Hypotheses (2024) Vol. 189, pp. 111417-111417
Closed Access | Times Cited: 1
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients
Stefan Agewall
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 5, pp. 367-369
Closed Access | Times Cited: 1
Renal Denervation in Heart Failure Treatment: Data for a Self-Fulfilling Prophecy
Kyriakos Dimitriadis, Panagιotis Iliakis, Nikolaos Pyrpyris, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 22, pp. 6656-6656
Open Access | Times Cited: 1
Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus—A Narrative Review
Roxana Brata, Andrei Pașcalău, Ovidiu Frăţilă, et al.
Healthcare (2024) Vol. 12, Iss. 23, pp. 2464-2464
Open Access
Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
Μelpomeni Peppa, Aspasia Manta, Ioanna Mavroeidi, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2526-2526
Open Access
Page 1

Scroll to top